LVTX

LAVA Therapeutics N.V. (LVTX) ESG Analysis Analysis (2026)

Invetso Score: 5.5/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.4 (Moderate)

LVTX’s disclosed environmental profile appears limited versus peers, with no provided evidence of emissions, energy, or waste controls that would indicate stronger operational stewardship.

The absence of reported R&D intensity in the supplied metrics suggests a less visible environmental innovation agenda than peers that disclose climate-related product or process investment.

No peer-benchmarkable environmental targets or third-party assurance were provided, which constrains confidence in relative performance versus more transparent life-science issuers.

Environmental risk appears manageable rather than advantaged, because the available data do not show a differentiated sustainability program relative to peers.

Social

Score:

The supplied metrics show no stock-based compensation burden, which can support workforce alignment versus peers that rely more heavily on equity incentives.

However, the absence of disclosed human-capital indicators such as turnover, safety, or diversity limits evidence that LVTX outperforms peers on social execution.

No product-safety, access, or community-impact disclosures were provided, leaving LVTX’s social positioning broadly in line with, but not above, peers.

Overall social visibility is moderate, because limited disclosure reduces reputational insight relative to peers with more comprehensive stakeholder reporting.

Governance

Score:

The reported debt-to-equity ratio of zero suggests a conservative capital structure versus leveraged peers, which can reduce governance pressure from creditor oversight.

Net debt to EBITDA of 2.65 indicates moderate leverage, so balance-sheet discipline is acceptable but not clearly superior to low-leverage peers.

Zero stock-based compensation in the supplied metrics may indicate lower dilution risk than peers, although it also limits evidence of long-term incentive alignment.

Governance disclosure remains incomplete on board independence, audit oversight, and shareholder rights, keeping LVTX near the peer median rather than clearly ahead.

Overall Score

Score:

LVTX appears broadly middle-of-pack on ESG versus peers, with limited disclosure and only modest balance-sheet and incentive advantages preventing a stronger relative score.

Score Driver: Limited ESG Disclosure Across Environmental And Social Dimensions Is The Main Constraint On Relative Positioning Versus Peers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on LAVA Therapeutics N.V.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →